A.O.D 9604 Frequently Asked Questions (Research Use Only) This FAQ provides structured, research-focused information about AOD9604, a synthetic peptide fragment supplied as a lyophilized powder for controlled laboratory environments
I had not put cobalt defiency and B12 defiency together at that point
SYNTHETIC.COM posts may contain financial reports and economic analysis that embody a unique view of trends and opportunities
: , () ,
: Targets tumor necrosis factor (TNF), a central inflammatory pathway addressed by biologics such as Humira and Enbrel Focuses on oral small molecules designed to deliver biologic-like efficacy Uses a proprietary AI-driven platform that models protein motion to identify new binding approaches Series A co-led by Lightstone Ventures and Samsara BioCapital, with participation from Roivant Sciences, YK Bioventures, and Eurofarma Ventures The company was founded by Woody Sherman, PsiTheras founder and chief innovation officer, and is led by Eric Shaff, CEO
[ \- Link Opens in New Tab]( Jin, J., Mulesa, L., & Carrilero Rouillet, M